In the past, understanding biological information, including DNA, required extensive time and effort. However, with advancements in DNA sequencing, AI, and single-cell genomics , the ability to analyze biological processes has improved dramatically . These genomic technologies enable personalized medicine , revolutionizing drug discovery and reshaping the medical industry. ARKG ETF invests in companies leading this genomic revolution , focusing on businesses that drive the future of healthcare innovation. ARK Investment Opportunity Report ETF Overview ETF Name : ARK Genomic Revolution ETF Ticker : ARKG Market Capitalization : $976.7 million (₩1.3 trillion, as of 25/6/13) Net Asset Value (NAV) : $23.47 (as of 25/6/13) Trading Volume : 3,782,685 shares (as of 25/6/13) Annual Expense Ratio : 0.75% Investment Strategy ARKG ETF focuses on companies driving genomic technology innovation , investing in the expanding markets of genomics analysis and drug development . The ETF...